Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2019

01-07-2019 | Breast Cancer | Breast Oncology

Germline Genetic Testing: What the Breast Surgeon Needs to Know

Authors: Jennifer K. Plichta, MD, MS, Molly L. Sebastian, MD, Linda A. Smith, MD, Carolyn S. Menendez, MD, Anita T. Johnson, MD, Sussan M. Bays, MD, David M. Euhus, MD, Edward J. Clifford, MD, Mena Jalali, MS, Scott H. Kurtzman, MD, Walton A. Taylor, MD, Kevin S. Hughes, MD

Published in: Annals of Surgical Oncology | Issue 7/2019

Login to get access

Abstract

Purpose

The American Society of Breast Surgeons (ASBrS) sought to provide educational guidelines for breast surgeons on how to incorporate genetic information and genomics into their practice.

Methods

A comprehensive nonsystematic review was performed of selected peer-reviewed literature. The Genetics Working Group of the ASBrS convened to develop guideline recommendations.

Results

Clinical and educational guidelines were prepared to outline the essential knowledge for breast surgeons to perform germline genetic testing and to incorporate the findings into their practice, which have been approved by the ASBrS Board of Directors.

Recommendations

Thousands of women in the USA would potentially benefit from genetic testing for BRCA1, BRCA2, and other breast cancer genes that markedly increase their risk of developing breast cancer. As genetic testing is now becoming more widely available, women should be made aware of these tests and consider testing. Breast surgeons are well positioned to help facilitate this process. The areas where surgeons need to be knowledgeable include: (1) identification of patients for initial breast cancer-related genetic testing, (2) identification of patients who tested negative in the past but now need updated testing, (3) initial cancer genetic testing, (4) retesting of patients who need their genetic testing updated, (5) cancer genetic test interpretation, posttest counseling and management, (6) management of variants of uncertain significance, (7) cascade genetic testing, (8) interpretation of genetic tests other than clinical cancer panels and the counseling and management required, and (9) interpretation of somatic genetic tests and the counseling and management required.
Literature
1.
Hughes KS. Genetic testing: what problem are we trying to solve? J Clin Oncol. 2017;35(34):3789–91.CrossRefPubMed
2.
Daly MB, Pilarski R, Berry MP, et al. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. National Comprehensive Cancer Network; July 30, 2018.
3.
2014 Professional Status Survey: Executive Summary. 2014.
4.
Noll A, Parekh JP, Zhou M, et al. Barriers to Llynch syndrome testing and preoperative result availability in early-onset colorectal cancer: a National Physician Survey study. Clin Transl Gastroenterol. 2018; 9(9):185.CrossRefPubMedPubMedCentral
5.
Hoskovec JM, Bennett RL, Carey ME, et al. Projecting the supply and demand for certified genetic counselors: a workforce study. J Genet Couns. 2018;27(1):16–20.CrossRefPubMed
6.
Childers KK, Maggard-Gibbons M, Macinko J, Childers CP. National distribution of cancer genetic testing in the United States: evidence for a gender disparity in hereditary breast and ovarian cancer. JAMA Oncol. 2018;4(6):876–79.CrossRefPubMedPubMedCentral
7.
Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800–06.CrossRefPubMedPubMedCentral
8.
Chen Z, Kolor K, Grosse SD, et al. Trends in utilization and costs of BRCA testing among women aged 18–64 years in the United States, 2003–2014. Genet Med. 2018;20(4):428–34.CrossRefPubMed
9.
Manickam K, Buchanan AH, Schwartz MB, et al. Exome sequencing–based screening for BRCA1/2 expected pathogenic variants among adult biobank participants. JAMA Netw Open. 2018;1(5):e182140.CrossRefPubMedPubMedCentral
10.
Drohan B, Roche CA, Cusack JC, Jr., Hughes KS. Hereditary breast and ovarian cancer and other hereditary syndromes: using technology to identify carriers. Ann Surg Oncol. 2012;19(6):1732–37.CrossRefPubMed
11.
Hall MJ, Olopade OI. Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol. 2006;24(14):2197–2203.CrossRefPubMed
12.
Forman AD, Hall MJ. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer. Breast J. 2009;15 Suppl 1:S56–62.CrossRefPubMed
13.
Halbert CH, Kessler LJ, Mitchell E. Genetic testing for inherited breast cancer risk in African Americans. Cancer Invest. 2005;23(4):285–95.CrossRefPubMed
14.
Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2018:Jco1801631.
15.
Guidelines miss cancer patients who could benefit from genetic testing: Part 1. In: Perspectives in Genetics: Empowering the Medical Community through Education and Insight. Vol 2018. Online: Invitae; 2018.
16.
Syngal S, Furniss C. Germline genetic testing for pancreatic ductal adenocarcinoma at time of diagnosis. JAMA. 2018;319(23):2383–85.CrossRefPubMed
17.
Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443–53.CrossRefPubMedPubMedCentral
18.
Guo X, Shi J, Cai Q, et al. Use of deep whole-genome sequencing data to identify structure risk variants in breast cancer susceptibility genes. Hum Mol Genet. 2018;27(5):853–59.CrossRefPubMedPubMedCentral
19.
Park S, Supek F, Lehner B. Systematic discovery of germline cancer predisposition genes through the identification of somatic second hits. Nat Commun. 2018;9(1):2601.CrossRefPubMedPubMedCentral
20.
Liang X, Vacher S, Boulai A, et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res. 2018;20(1):88.CrossRefPubMedPubMedCentral
21.
Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017;35(20):2232–39.CrossRefPubMedPubMedCentral
22.
Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117(23):5334–43.CrossRefPubMed
23.
Morman NA, Byrne L, Collins C, Reynolds K, Bell JG. Breast cancer risk assessment at the time of screening mammography: perceptions and clinical management outcomes for women at high risk. J Genet Couns. 2017;26(4):776–84.CrossRefPubMed
24.
Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34(13):1460–68.CrossRefPubMedPubMedCentral
25.
Maxwell KN, Wubbenhorst B, D’Andrea K, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med. 2015;17(8):630–38.CrossRefPubMed
26.
Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1(7):943–51.CrossRefPubMed
27.
Whitworth P, Beitsch P, Arnell C, et al. Impact of payer constraints on access to genetic testing. J Oncol Pract. 2017;13(1):e47–56.CrossRefPubMed
28.
29.
30.
31.
Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015;33(31):3660–67.CrossRefPubMed
32.
33.
34.
Beitsch PD, Whitworth PW. Can breast surgeons provide breast cancer genetic testing? An American Society of Breast Surgeons survey. Ann Surg Oncol. 2014;21(13):4104–08.CrossRefPubMed
35.
Hughes KS. Personal community with Myriad Genetics. In: Kevin Hughes M (ed); 2018.
36.
37.
Slavin TP, Van Tongeren LR, Behrendt CE, et al. Prospective study of cancer genetic variants: variation in rate of reclassification by ancestry. J Natl Cancer Inst. 2018.
38.
Augusto BM, Lake P, Scherr CL, Couch FJ, Lindor NM, Vadaparampil ST. From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Commun Genet. 2018;9(3):209–15.CrossRef
39.
Roberts MC, Dotson WD, DeVore CS, et al. Delivery of cascade screening for hereditary conditions: a scoping review of the literature. Health Affairs (Project Hope). 2018;37(5):801–08.CrossRef
40.
Katapodi MC, Jung M, Schafenacker AM, et al. Development of a Web-based family intervention for BRCA carriers and their biological relatives: acceptability, feasibility, and usability study. JMIR Cancer. 2018;4(1):e7.CrossRefPubMedPubMedCentral
41.
Nilsson MP, Emmertz M, Kristoffersson U, et al. Germline mutations in BRCA1 and BRCA2 incidentally revealed in a biobank research study: experiences from re-contacting mutation carriers and relatives. J Community Genet. 2018;9(3):201–08.CrossRef
42.
Buchanan AH, Manickam K, Meyer MN, et al. Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants. Genet Med. 2018;20(5):554–8.CrossRefPubMed
43.
Mandelker D, Zhang L, Kemel Y, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318(9):825–35.CrossRefPubMedPubMedCentral
44.
45.
Pritzlaff M, Yorczyk A, Robinson LS, et al. An internal performance assessment of CancerGene Connect: an electronic tool to streamline, measure and improve the genetic counseling process. J Genet Couns. 2014;23(6):1034–44.CrossRefPubMedPubMedCentral
46.
Metadata
Title
Germline Genetic Testing: What the Breast Surgeon Needs to Know
Authors
Jennifer K. Plichta, MD, MS
Molly L. Sebastian, MD
Linda A. Smith, MD
Carolyn S. Menendez, MD
Anita T. Johnson, MD
Sussan M. Bays, MD
David M. Euhus, MD
Edward J. Clifford, MD
Mena Jalali, MS
Scott H. Kurtzman, MD
Walton A. Taylor, MD
Kevin S. Hughes, MD
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07341-8

Other articles of this Issue 7/2019

Annals of Surgical Oncology 7/2019 Go to the issue

Colorectal Cancer

Longer Intervals from Neoadjuvant Therapy to Rectal Cancer Surgery: The Clock is Ticking…

Health Services Research and Global Oncology

Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database

Peritoneal Surface Malignancy

Selection and Characteristics of Patients with Peritoneal Dissemination from Appendiceal Cancer with Exceptional/Poor Survival After CRS/HIPEC

Health Services Research and Global Oncology

Outcomes of Open Versus Minimally Invasive Ivor-Lewis Esophagectomy for Cancer: A Propensity-Score Matched Analysis of NSQIP Database

Pancreatic Tumors

Exosomes from Pancreatic Juice: A Step Closer to the Holy Grail?

Gastrointestinal Oncology

Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study